Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023

Data from oral presentation adds to growing body of evidence supporting the profile of PRX012, which is designed to target all aggregated forms of amyloid beta with high binding... | March 31, 2023

Related Keywords

Sweden ,Gothenburg ,Vastra Gotalands Lan ,Wagner Zago ,Prothena Corporation ,International Conference On Alzheimer ,Exchange Commission ,Nasdaq ,Forum Discussions ,Company On Twitter Prothenacorp ,Plasmon Resonance ,Chief Scientific Officer ,Prothena Activities ,Disease Modifying Treatments ,Taking Stock ,Two Forum Discussions ,From Basics ,Anti Tau Therapies ,Clinical Trials ,Annual Report ,Prothena Corporation Plc Stock Exchange ,News ,Information ,Press Release ,Data ,Rom ,Mural ,Presentation ,Odds ,O ,Rowing ,Body ,F ,Evidence ,Supporting ,The ,Profile ,Which ,Us ,Esigned ,Target ,Wall ,Aggregated ,Eforms ,Amyloid ,Meta ,Ith ,Igh Prta Ie00b91xrn20 ,